Syros Pharmaceuticals's total assets for Q3 2024 were $85.00M, a decrease of -20.36% from the previous quarter. SYRS total liabilities were $96.12M for the fiscal quarter, a -15.00% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.